Does the media refer more to ANRO or KPTI?

In the previous week, Alto Neuroscience had 5 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 7 mentions for Alto Neuroscience and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Alto Neuroscience's score of 0.55 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to REPL or KPTI?

In the previous week, Replimune Group had 5 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 7 mentions for Replimune Group and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Replimune Group's score of 0.95 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GLAS or KPTI?

Glass House Brands has higher revenue and earnings than Karyopharm Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $176.02M 4.92 N/A N/A N/A Karyopharm Therapeutics $146.07M 1.48 -$196.04M -$15.09 N/A

Is GLAS or KPTI more profitable?

Glass House Brands has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Karyopharm Therapeutics -129.02% N/A -120.29%

Does the media refer more to GLAS or KPTI?

In the previous week, Glass House Brands had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for Glass House Brands and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Glass House Brands' score of 0.15 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Karyopharm Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, IVA or KPTI?

Karyopharm Therapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 214.05 -$400.67M N/A N/A Karyopharm Therapeutics $146.07M 1.48 -$196.04M -$15.09 N/A

Is IVA or KPTI more profitable?

Inventiva has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Karyopharm Therapeutics -129.02% N/A -120.29%

Does the media refer more to IVA or KPTI?

In the previous week, Inventiva had 4 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 6 mentions for Inventiva and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Inventiva's score of 0.26 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Karyopharm Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KPTI or TBPH?

In the previous week, Theravance Biopharma had 2 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Theravance Biopharma and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Theravance Biopharma's score of 0.20 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Karyopharm Therapeutics (KPTI) Competitors

$9.51 +0.13 (+1.39%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$9.11 -0.40 (-4.24%)

As of 07/17/2026 07:49 PM Eastern

Compare

KPTI vs. ANRO, REPL, GLAS, IVA, and TBPH

Should you buy Karyopharm Therapeutics stock or one of its competitors? MarketBeat compares Karyopharm Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Karyopharm Therapeutics include Alto Neuroscience (ANRO), Replimune Group (REPL), Glass House Brands (GLAS), Inventiva (IVA), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical products" industry.

How does Karyopharm Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Alto Neuroscience currently has a consensus target price of $35.25, suggesting a potential upside of 27.98%. Karyopharm Therapeutics has a consensus target price of $17.17, suggesting a potential upside of 80.51%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Alto Neuroscience has higher earnings, but lower revenue than Karyopharm Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Karyopharm Therapeutics	$146.07M	1.48	-$196.04M	-$15.09	N/A

In the previous week, Alto Neuroscience had 5 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 7 mentions for Alto Neuroscience and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Alto Neuroscience's score of 0.55 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Karyopharm Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alto Neuroscience has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Alto Neuroscience has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Summary

Alto Neuroscience and Karyopharm Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Replimune Group has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Replimune Group currently has a consensus price target of $8.13, suggesting a potential downside of 20.58%. Karyopharm Therapeutics has a consensus price target of $17.17, suggesting a potential upside of 80.51%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Replimune Group has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

Karyopharm Therapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Karyopharm Therapeutics	$146.07M	1.48	-$196.04M	-$15.09	N/A

In the previous week, Replimune Group had 5 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 7 mentions for Replimune Group and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Replimune Group's score of 0.95 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Karyopharm Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Karyopharm Therapeutics beats Replimune Group on 9 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Glass House Brands has higher revenue and earnings than Karyopharm Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$176.02M	4.92	N/A	N/A	N/A
Karyopharm Therapeutics	$146.07M	1.48	-$196.04M	-$15.09	N/A

In the previous week, Glass House Brands had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for Glass House Brands and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Glass House Brands' score of 0.15 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glass House Brands presently has a consensus target price of $17.00, suggesting a potential upside of 57.70%. Karyopharm Therapeutics has a consensus target price of $17.17, suggesting a potential upside of 80.51%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Glass House Brands has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Summary

Karyopharm Therapeutics beats Glass House Brands on 6 of the 11 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Inventiva has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Inventiva has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Karyopharm Therapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	214.05	-$400.67M	N/A	N/A
Karyopharm Therapeutics	$146.07M	1.48	-$196.04M	-$15.09	N/A

In the previous week, Inventiva had 4 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 6 mentions for Inventiva and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Inventiva's score of 0.26 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva presently has a consensus price target of $16.56, indicating a potential upside of 258.35%. Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 80.51%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Inventiva beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Theravance Biopharma?

Karyopharm Therapeutics (NASDAQ:KPTI) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Theravance Biopharma has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.48	-$196.04M	-$15.09	N/A
Theravance Biopharma	$107.46M	8.12	$105.89M	$2.20	7.70

In the previous week, Theravance Biopharma had 2 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Theravance Biopharma and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.34 beat Theravance Biopharma's score of 0.20 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Karyopharm Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Karyopharm Therapeutics currently has a consensus target price of $17.17, indicating a potential upside of 80.51%. Theravance Biopharma has a consensus target price of $19.40, indicating a potential upside of 14.59%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Karyopharm Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has a net margin of 104.34% compared to Karyopharm Therapeutics' net margin of -129.02%. Theravance Biopharma's return on equity of 18.84% beat Karyopharm Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Theravance Biopharma	104.34%	18.84%	10.94%

Summary

Theravance Biopharma beats Karyopharm Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPTI vs. The Competition

Export

Metric	Karyopharm Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$215.53M	$3.06B	$6.87B	$12.28B
Dividend Yield	N/A	2.06%	2.67%	9.34%
P/E Ratio	-0.63	20.17	27.25	23.92
Price / Sales	1.48	348.29	492.88	72.75
Price / Cash	N/A	57.26	52.99	60.41
Price / Book	-0.59	4.26	10.69	6.18
Net Income	-$196.04M	$65.46M	$3.59B	$332.29M
7 Day Performance	-8.03%	-3.20%	-2.20%	-2.05%
1 Month Performance	5.43%	0.70%	1.63%	-2.18%
1 Year Performance	147.01%	19.10%	25.64%	17.67%

Karyopharm Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPTI Karyopharm Therapeutics	2.5438 of 5 stars	$9.51 +1.4%	$17.17 +80.5%	+147.0%	$215.53M	$146.07M	N/A	380	News Coverage Positive News
ANRO Alto Neuroscience	2.4698 of 5 stars	$28.10 +6.1%	$35.25 +25.5%	+890.8%	$929.29M	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down High Trading Volume
REPL Replimune Group	1.2032 of 5 stars	$9.94 -9.6%	$8.13 -18.3%	-15.4%	$922.56M	N/A	N/A	210	News Coverage
GLAS Glass House Brands	N/A	$11.45 -3.0%	$17.00 +48.5%	N/A	$919.20M	$176.02M	N/A	N/A	News Coverage
IVA Inventiva	2.5214 of 5 stars	$4.30 flat	$16.56 +285.0%	+40.6%	$893.14M	$5.07M	N/A	100	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPTI) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. ANRO, REPL, GLAS, IVA, and TBPH

How does Karyopharm Therapeutics compare to Alto Neuroscience?

Summary

How does Karyopharm Therapeutics compare to Replimune Group?

Summary

How does Karyopharm Therapeutics compare to Glass House Brands?

Summary

How does Karyopharm Therapeutics compare to Inventiva?

Summary

How does Karyopharm Therapeutics compare to Theravance Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. ANRO, REPL, GLAS, IVA, and TBPH

How does Karyopharm Therapeutics compare to Alto Neuroscience?

Do analysts recommend ANRO or KPTI?

Which has better earnings and valuation, ANRO or KPTI?

Does the media refer more to ANRO or KPTI?

Do insiders & institutionals have more ownership in ANRO or KPTI?

Which has more volatility and risk, ANRO or KPTI?

Is ANRO or KPTI more profitable?

Summary

How does Karyopharm Therapeutics compare to Replimune Group?

Do institutionals and insiders have more ownership in REPL or KPTI?

Is REPL or KPTI more profitable?

Do analysts prefer REPL or KPTI?

Which has more volatility & risk, REPL or KPTI?

Which has higher valuation and earnings, REPL or KPTI?

Does the media refer more to REPL or KPTI?

Summary

How does Karyopharm Therapeutics compare to Glass House Brands?

Which has preferable valuation & earnings, GLAS or KPTI?

Does the media refer more to GLAS or KPTI?

Do analysts prefer GLAS or KPTI?

Do institutionals & insiders have more ownership in GLAS or KPTI?

Is GLAS or KPTI more profitable?

Summary

How does Karyopharm Therapeutics compare to Inventiva?

Is IVA or KPTI more profitable?

Do institutionals and insiders believe in IVA or KPTI?

Which has more risk and volatility, IVA or KPTI?

Which has preferable valuation and earnings, IVA or KPTI?

Does the media refer more to IVA or KPTI?

Do analysts rate IVA or KPTI?

Summary

How does Karyopharm Therapeutics compare to Theravance Biopharma?

Which has preferable valuation and earnings, KPTI or TBPH?

Does the media prefer KPTI or TBPH?

Do insiders & institutionals hold more shares of KPTI or TBPH?

Which has more volatility and risk, KPTI or TBPH?

Do analysts prefer KPTI or TBPH?

Is KPTI or TBPH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools